Here are the 424B prospectus supplements from Telomir Pharmaceuticals, Inc. (TELO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TELO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELO filings page.
Telomir Pharmaceuticals, Inc. registered up to 5,292,810 common shares for resale by selling securityholders. The shares include 4,900,750 outstanding shares and 392,060 shares issuable upon exercise of placement agent warrants.
Telomir will not receive proceeds from selling securityholders’ resales, but may receive the warrant exercise price if warrants are exercised for cash. The completed private placement generated approximately $5.6 million in gross proceeds before placement agent fees and other offering expenses; purchasers paid $1.16 per share on October 5, 2026, and $1.13 per share on October 9, 2026.
Telomir is developing Telomir-Zn, an investigational oral small molecule. The FDA cleared its IND application for advanced or metastatic triple-negative breast cancer in April 2026, and the planned Phase 1/2 study is expected to enroll approximately 76 patients. Telomir completed its acquisition of TELI Pharmaceuticals on April 22, 2026, obtaining exclusive worldwide development and commercialization rights to Telomir-Zn.